Titre : Composés de pyridinium

Composés de pyridinium : Questions médicales fréquentes

Termes MeSH sélectionnés :

Cholangiocarcinoma
{ "@context": "https://schema.org", "@graph": [ { "@type": "MedicalWebPage", "name": "Composés de pyridinium : Questions médicales les plus fréquentes", "headline": "Composés de pyridinium : Comprendre les symptômes, diagnostics et traitements", "description": "Guide complet et accessible sur les Composés de pyridinium : explications, diagnostics, traitements et prévention. Information médicale validée destinée aux patients.", "datePublished": "2024-04-05", "dateModified": "2025-03-31", "inLanguage": "fr", "medicalAudience": [ { "@type": "MedicalAudience", "name": "Grand public", "audienceType": "Patient", "healthCondition": { "@type": "MedicalCondition", "name": "Composés de pyridinium" }, "suggestedMinAge": 18, "suggestedGender": "unisex" }, { "@type": "MedicalAudience", "name": "Médecins", "audienceType": "Physician", "geographicArea": { "@type": "AdministrativeArea", "name": "France" } }, { "@type": "MedicalAudience", "name": "Chercheurs", "audienceType": "Researcher", "geographicArea": { "@type": "AdministrativeArea", "name": "International" } } ], "reviewedBy": { "@type": "Person", "name": "Dr Olivier Menir", "jobTitle": "Expert en Médecine", "description": "Expert en Médecine, Optimisation des Parcours de Soins et Révision Médicale", "url": "/static/pages/docteur-olivier-menir.html", "alumniOf": { "@type": "EducationalOrganization", "name": "Université Paris Descartes" } }, "isPartOf": { "@type": "MedicalWebPage", "name": "Pyridines", "url": "https://questionsmedicales.fr/mesh/D011725", "about": { "@type": "MedicalCondition", "name": "Pyridines", "code": { "@type": "MedicalCode", "code": "D011725", "codingSystem": "MeSH" }, "identifier": { "@type": "PropertyValue", "propertyID": "MeSH Tree", "value": "D03.383.725" } } }, "hasPart": [ { "@type": "MedicalWebPage", "name": "Cétylpyridinium", "alternateName": "Cetylpyridinium", "url": "https://questionsmedicales.fr/mesh/D002594", "about": { "@type": "MedicalCondition", "name": "Cétylpyridinium", "code": { "@type": "MedicalCode", "code": "D002594", "codingSystem": "MeSH" }, "identifier": { "@type": "PropertyValue", "propertyID": "MeSH Tree", "value": "D03.383.725.762.232" } } }, { "@type": "MedicalWebPage", "name": "Diquat", "alternateName": "Diquat", "url": "https://questionsmedicales.fr/mesh/D004178", "about": { "@type": "MedicalCondition", "name": "Diquat", "code": { "@type": "MedicalCode", "code": "D004178", "codingSystem": "MeSH" }, "identifier": { "@type": "PropertyValue", "propertyID": "MeSH Tree", "value": "D03.383.725.762.352" } } }, { "@type": "MedicalWebPage", "name": "1-Méthyl-4-phényl-pyridinium", "alternateName": "1-Methyl-4-phenylpyridinium", "url": "https://questionsmedicales.fr/mesh/D015655", "about": { "@type": "MedicalCondition", "name": "1-Méthyl-4-phényl-pyridinium", "code": { "@type": "MedicalCode", "code": "D015655", "codingSystem": "MeSH" }, "identifier": { "@type": "PropertyValue", "propertyID": "MeSH Tree", "value": "D03.383.725.762.550" } } }, { "@type": "MedicalWebPage", "name": "Chlorure d'obidoxime", "alternateName": "Obidoxime Chloride", "url": "https://questionsmedicales.fr/mesh/D009768", "about": { "@type": "MedicalCondition", "name": "Chlorure d'obidoxime", "code": { "@type": "MedicalCode", "code": "D009768", "codingSystem": "MeSH" }, "identifier": { "@type": "PropertyValue", "propertyID": "MeSH Tree", "value": "D03.383.725.762.600" } } }, { "@type": "MedicalWebPage", "name": "Paraquat", "alternateName": "Paraquat", "url": "https://questionsmedicales.fr/mesh/D010269", "about": { "@type": "MedicalCondition", "name": "Paraquat", "code": { "@type": "MedicalCode", "code": "D010269", "codingSystem": "MeSH" }, "identifier": { "@type": "PropertyValue", "propertyID": "MeSH Tree", "value": "D03.383.725.762.621" } } }, { "@type": "MedicalWebPage", "name": "Bromure de pyridostigmine", "alternateName": "Pyridostigmine Bromide", "url": "https://questionsmedicales.fr/mesh/D011729", "about": { "@type": "MedicalCondition", "name": "Bromure de pyridostigmine", "code": { "@type": "MedicalCode", "code": "D011729", "codingSystem": "MeSH" }, "identifier": { "@type": "PropertyValue", "propertyID": "MeSH Tree", "value": "D03.383.725.762.740" } } }, { "@type": "MedicalWebPage", "name": "Trimédoxime", "alternateName": "Trimedoxime", "url": "https://questionsmedicales.fr/mesh/D014289", "about": { "@type": "MedicalCondition", "name": "Trimédoxime", "code": { "@type": "MedicalCode", "code": "D014289", "codingSystem": "MeSH" }, "identifier": { "@type": "PropertyValue", "propertyID": "MeSH Tree", "value": "D03.383.725.762.900" } } }, { "@type": "MedicalWebPage", "name": "Viologènes", "alternateName": "Viologens", "url": "https://questionsmedicales.fr/mesh/D014755", "about": { "@type": "MedicalCondition", "name": "Viologènes", "code": { "@type": "MedicalCode", "code": "D014755", "codingSystem": "MeSH" }, "identifier": { "@type": "PropertyValue", "propertyID": "MeSH Tree", "value": "D03.383.725.762.925" } }, "hasPart": [ { "@type": "MedicalWebPage", "name": "Benzyl viologène", "alternateName": "Benzyl Viologen", "url": "https://questionsmedicales.fr/mesh/D001594", "about": { "@type": "MedicalCondition", "name": "Benzyl viologène", "code": { "@type": "MedicalCode", "code": "D001594", "codingSystem": "MeSH" }, "identifier": { "@type": "PropertyValue", "propertyID": "MeSH Tree", "value": "D03.383.725.762.925.100" } } } ] } ], "about": { "@type": "MedicalCondition", "name": "Composés de pyridinium", "alternateName": "Pyridinium Compounds", "code": { "@type": "MedicalCode", "code": "D011726", "codingSystem": "MeSH" } }, "author": [ { "@type": "Person", "name": "Sungwoo Hong", "url": "https://questionsmedicales.fr/author/Sungwoo%20Hong", "affiliation": { "@type": "Organization", "name": "Department of Chemistry, Korea Advanced Institute of Science and Technology (KAIST) Daejeon 34141 Korea hongorg@kaist.ac.kr." } }, { "@type": "Person", "name": "Werner Fudickar", "url": "https://questionsmedicales.fr/author/Werner%20Fudickar", "affiliation": { "@type": "Organization", "name": "Department of Chemistry, University of Potsdam, Potsdam, Germany." } }, { "@type": "Person", "name": "Torsten Linker", "url": "https://questionsmedicales.fr/author/Torsten%20Linker", "affiliation": { "@type": "Organization", "name": "Department of Chemistry, University of Potsdam, Potsdam, Germany." } }, { "@type": "Person", "name": "Lihua Luo", "url": "https://questionsmedicales.fr/author/Lihua%20Luo", "affiliation": { "@type": "Organization", "name": "Key Laboratory of Green Chemistry and Technology, Ministry of Education, College of Chemistry, Sichuan University, Chengdu, Sichuan 610064, P. R. China." } }, { "@type": "Person", "name": "Rui Sun", "url": "https://questionsmedicales.fr/author/Rui%20Sun", "affiliation": { "@type": "Organization", "name": "Key Laboratory of Green Chemistry and Technology, Ministry of Education, College of Chemistry, Sichuan University, Chengdu, Sichuan 610064, P. R. China." } } ], "citation": [ { "@type": "ScholarlyArticle", "name": "[Current Studies and Evidence in Cholangiocarcinoma].", "datePublished": "2022-07-21", "url": "https://questionsmedicales.fr/article/35863357", "identifier": { "@type": "PropertyValue", "propertyID": "DOI", "value": "10.1055/a-1844-0267" } }, { "@type": "ScholarlyArticle", "name": "Pemigatinib: A Review in Advanced Cholangiocarcinoma.", "datePublished": "2024-01-11", "url": "https://questionsmedicales.fr/article/38206555", "identifier": { "@type": "PropertyValue", "propertyID": "DOI", "value": "10.1007/s11523-023-01024-x" } }, { "@type": "ScholarlyArticle", "name": "Challenges in Diagnosing and Reporting Cholangiocarcinoma.", "datePublished": "2023-06-23", "url": "https://questionsmedicales.fr/article/37536891", "identifier": { "@type": "PropertyValue", "propertyID": "DOI", "value": "10.1016/j.path.2023.04.012" } }, { "@type": "ScholarlyArticle", "name": "Endoscopic management of perihilar cholangiocarcinoma.", "datePublished": "2022-06-02", "url": "https://questionsmedicales.fr/article/35377509", "identifier": { "@type": "PropertyValue", "propertyID": "DOI", "value": "10.1111/den.14317" } }, { "@type": "ScholarlyArticle", "name": "\"Long-term follow-up of liver transplantation in incidental intrahepatic cholangiocarcinoma and mixed hepatocellular-cholangiocarcinoma\".", "datePublished": "2023-04-28", "url": "https://questionsmedicales.fr/article/37119950", "identifier": { "@type": "PropertyValue", "propertyID": "DOI", "value": "10.1016/j.cireng.2023.04.010" } } ], "breadcrumb": { "@type": "BreadcrumbList", "itemListElement": [ { "@type": "ListItem", "position": 1, "name": "questionsmedicales.fr", "item": "https://questionsmedicales.fr" }, { "@type": "ListItem", "position": 2, "name": "Composés hétérocycliques", "item": "https://questionsmedicales.fr/mesh/D006571" }, { "@type": "ListItem", "position": 3, "name": "Composés hétéromonocycliques", "item": "https://questionsmedicales.fr/mesh/D006573" }, { "@type": "ListItem", "position": 4, "name": "Pyridines", "item": "https://questionsmedicales.fr/mesh/D011725" }, { "@type": "ListItem", "position": 5, "name": "Composés de pyridinium", "item": "https://questionsmedicales.fr/mesh/D011726" } ] } }, { "@type": "MedicalWebPage", "name": "Article complet : Composés de pyridinium - Questions et réponses", "headline": "Questions et réponses médicales fréquentes sur Composés de pyridinium", "description": "Une compilation de questions et réponses structurées, validées par des experts médicaux.", "datePublished": "2025-05-19", "inLanguage": "fr", "hasPart": [ { "@type": "MedicalWebPage", "name": "Diagnostic", "headline": "Diagnostic sur Composés de pyridinium", "description": "Comment diagnostiquer une intoxication aux composés de pyridinium ?\nQuels tests sont utilisés pour détecter les composés de pyridinium ?\nQuels symptômes indiquent une exposition aux pyridiniums ?\nLes tests urinaires peuvent-ils détecter les pyridiniums ?\nQuelle est l'importance de l'historique médical dans le diagnostic ?", "url": "https://questionsmedicales.fr/mesh/D011726?mesh_terms=Cholangiocarcinoma&page=3#section-diagnostic" }, { "@type": "MedicalWebPage", "name": "Symptômes", "headline": "Symptômes sur Composés de pyridinium", "description": "Quels sont les symptômes courants d'une exposition aux pyridiniums ?\nLes composés de pyridinium provoquent-ils des effets neurologiques ?\nY a-t-il des symptômes cutanés associés aux pyridiniums ?\nLes symptômes varient-ils selon le type de pyridinium ?\nComment les symptômes évoluent-ils avec le temps ?", "url": "https://questionsmedicales.fr/mesh/D011726?mesh_terms=Cholangiocarcinoma&page=3#section-symptômes" }, { "@type": "MedicalWebPage", "name": "Prévention", "headline": "Prévention sur Composés de pyridinium", "description": "Quelles mesures préventives peuvent réduire l'exposition aux pyridiniums ?\nLes formations sont-elles nécessaires pour manipuler des pyridiniums ?\nComment stocker les composés de pyridinium en toute sécurité ?\nLes fuites de pyridiniums peuvent-elles être évitées ?\nQuelles sont les recommandations pour les laboratoires ?", "url": "https://questionsmedicales.fr/mesh/D011726?mesh_terms=Cholangiocarcinoma&page=3#section-prévention" }, { "@type": "MedicalWebPage", "name": "Traitements", "headline": "Traitements sur Composés de pyridinium", "description": "Quel est le traitement principal en cas d'intoxication aux pyridiniums ?\nLes soins de soutien sont-ils nécessaires pour les patients exposés ?\nQuels antidotes sont utilisés contre les pyridiniums ?\nLa dialyse est-elle efficace pour éliminer les pyridiniums ?\nComment prévenir les complications lors du traitement ?", "url": "https://questionsmedicales.fr/mesh/D011726?mesh_terms=Cholangiocarcinoma&page=3#section-traitements" }, { "@type": "MedicalWebPage", "name": "Complications", "headline": "Complications sur Composés de pyridinium", "description": "Quelles complications peuvent survenir après une exposition aux pyridiniums ?\nLes effets à long terme des pyridiniums sont-ils connus ?\nComment les complications sont-elles gérées ?\nLes complications peuvent-elles être évitées ?\nQuels sont les signes d'alerte pour des complications graves ?", "url": "https://questionsmedicales.fr/mesh/D011726?mesh_terms=Cholangiocarcinoma&page=3#section-complications" }, { "@type": "MedicalWebPage", "name": "Facteurs de risque", "headline": "Facteurs de risque sur Composés de pyridinium", "description": "Quels sont les principaux facteurs de risque d'exposition aux pyridiniums ?\nL'âge influence-t-il la sensibilité aux pyridiniums ?\nLes antécédents médicaux augmentent-ils le risque d'intoxication ?\nLes conditions environnementales jouent-elles un rôle ?\nLes interactions médicamenteuses sont-elles un facteur de risque ?", "url": "https://questionsmedicales.fr/mesh/D011726?mesh_terms=Cholangiocarcinoma&page=3#section-facteurs de risque" } ] }, { "@type": "FAQPage", "mainEntity": [ { "@type": "Question", "name": "Comment diagnostiquer une intoxication aux composés de pyridinium ?", "position": 1, "acceptedAnswer": { "@type": "Answer", "text": "Le diagnostic repose sur l'historique d'exposition et des tests sanguins spécifiques." } }, { "@type": "Question", "name": "Quels tests sont utilisés pour détecter les composés de pyridinium ?", "position": 2, "acceptedAnswer": { "@type": "Answer", "text": "Des analyses chromatographiques et spectrométriques sont couramment utilisées." } }, { "@type": "Question", "name": "Quels symptômes indiquent une exposition aux pyridiniums ?", "position": 3, "acceptedAnswer": { "@type": "Answer", "text": "Les symptômes incluent des nausées, des vomissements et des troubles neurologiques." } }, { "@type": "Question", "name": "Les tests urinaires peuvent-ils détecter les pyridiniums ?", "position": 4, "acceptedAnswer": { "@type": "Answer", "text": "Oui, certains tests urinaires peuvent révéler la présence de métabolites pyridiniques." } }, { "@type": "Question", "name": "Quelle est l'importance de l'historique médical dans le diagnostic ?", "position": 5, "acceptedAnswer": { "@type": "Answer", "text": "L'historique médical aide à établir un lien entre les symptômes et l'exposition aux pyridiniums." } }, { "@type": "Question", "name": "Quels sont les symptômes courants d'une exposition aux pyridiniums ?", "position": 6, "acceptedAnswer": { "@type": "Answer", "text": "Les symptômes incluent des douleurs abdominales, des vertiges et des troubles respiratoires." } }, { "@type": "Question", "name": "Les composés de pyridinium provoquent-ils des effets neurologiques ?", "position": 7, "acceptedAnswer": { "@type": "Answer", "text": "Oui, ils peuvent causer des maux de tête, des convulsions et des troubles de la conscience." } }, { "@type": "Question", "name": "Y a-t-il des symptômes cutanés associés aux pyridiniums ?", "position": 8, "acceptedAnswer": { "@type": "Answer", "text": "Des éruptions cutanées et des irritations peuvent survenir après contact avec ces composés." } }, { "@type": "Question", "name": "Les symptômes varient-ils selon le type de pyridinium ?", "position": 9, "acceptedAnswer": { "@type": "Answer", "text": "Oui, les symptômes peuvent varier en fonction de la structure chimique et de la dose." } }, { "@type": "Question", "name": "Comment les symptômes évoluent-ils avec le temps ?", "position": 10, "acceptedAnswer": { "@type": "Answer", "text": "Les symptômes peuvent s'aggraver sans traitement approprié, nécessitant une intervention rapide." } }, { "@type": "Question", "name": "Quelles mesures préventives peuvent réduire l'exposition aux pyridiniums ?", "position": 11, "acceptedAnswer": { "@type": "Answer", "text": "Utiliser des équipements de protection individuelle lors de la manipulation de ces composés." } }, { "@type": "Question", "name": "Les formations sont-elles nécessaires pour manipuler des pyridiniums ?", "position": 12, "acceptedAnswer": { "@type": "Answer", "text": "Oui, des formations sur la sécurité chimique sont essentielles pour les travailleurs exposés." } }, { "@type": "Question", "name": "Comment stocker les composés de pyridinium en toute sécurité ?", "position": 13, "acceptedAnswer": { "@type": "Answer", "text": "Les stocker dans des contenants hermétiques et étiquetés, à l'écart des sources de chaleur." } }, { "@type": "Question", "name": "Les fuites de pyridiniums peuvent-elles être évitées ?", "position": 14, "acceptedAnswer": { "@type": "Answer", "text": "Oui, en vérifiant régulièrement les équipements et en respectant les protocoles de sécurité." } }, { "@type": "Question", "name": "Quelles sont les recommandations pour les laboratoires ?", "position": 15, "acceptedAnswer": { "@type": "Answer", "text": "Les laboratoires doivent suivre des protocoles stricts de manipulation et de stockage des pyridiniums." } }, { "@type": "Question", "name": "Quel est le traitement principal en cas d'intoxication aux pyridiniums ?", "position": 16, "acceptedAnswer": { "@type": "Answer", "text": "Le traitement principal est la décontamination et l'administration d'antidotes spécifiques." } }, { "@type": "Question", "name": "Les soins de soutien sont-ils nécessaires pour les patients exposés ?", "position": 17, "acceptedAnswer": { "@type": "Answer", "text": "Oui, des soins de soutien, comme l'hydratation et la surveillance, sont souvent requis." } }, { "@type": "Question", "name": "Quels antidotes sont utilisés contre les pyridiniums ?", "position": 18, "acceptedAnswer": { "@type": "Answer", "text": "Des antidotes comme l'atropine peuvent être administrés pour contrer les effets toxiques." } }, { "@type": "Question", "name": "La dialyse est-elle efficace pour éliminer les pyridiniums ?", "position": 19, "acceptedAnswer": { "@type": "Answer", "text": "La dialyse peut être envisagée dans les cas graves d'intoxication pour éliminer les toxines." } }, { "@type": "Question", "name": "Comment prévenir les complications lors du traitement ?", "position": 20, "acceptedAnswer": { "@type": "Answer", "text": "Une surveillance étroite et un traitement rapide des symptômes sont essentiels pour prévenir les complications." } }, { "@type": "Question", "name": "Quelles complications peuvent survenir après une exposition aux pyridiniums ?", "position": 21, "acceptedAnswer": { "@type": "Answer", "text": "Des complications comme des lésions organiques, des troubles neurologiques et respiratoires peuvent survenir." } }, { "@type": "Question", "name": "Les effets à long terme des pyridiniums sont-ils connus ?", "position": 22, "acceptedAnswer": { "@type": "Answer", "text": "Oui, des effets à long terme incluent des troubles cognitifs et des problèmes respiratoires chroniques." } }, { "@type": "Question", "name": "Comment les complications sont-elles gérées ?", "position": 23, "acceptedAnswer": { "@type": "Answer", "text": "Les complications nécessitent une prise en charge médicale spécialisée et un suivi régulier." } }, { "@type": "Question", "name": "Les complications peuvent-elles être évitées ?", "position": 24, "acceptedAnswer": { "@type": "Answer", "text": "Oui, une intervention rapide et un traitement approprié peuvent réduire le risque de complications." } }, { "@type": "Question", "name": "Quels sont les signes d'alerte pour des complications graves ?", "position": 25, "acceptedAnswer": { "@type": "Answer", "text": "Des signes comme des difficultés respiratoires, des convulsions ou une confusion mentale doivent alerter." } }, { "@type": "Question", "name": "Quels sont les principaux facteurs de risque d'exposition aux pyridiniums ?", "position": 26, "acceptedAnswer": { "@type": "Answer", "text": "Les travailleurs en chimie, agriculture et industrie sont les plus exposés aux pyridiniums." } }, { "@type": "Question", "name": "L'âge influence-t-il la sensibilité aux pyridiniums ?", "position": 27, "acceptedAnswer": { "@type": "Answer", "text": "Oui, les jeunes enfants et les personnes âgées sont plus sensibles aux effets toxiques." } }, { "@type": "Question", "name": "Les antécédents médicaux augmentent-ils le risque d'intoxication ?", "position": 28, "acceptedAnswer": { "@type": "Answer", "text": "Oui, des antécédents de maladies respiratoires ou neurologiques peuvent augmenter le risque." } }, { "@type": "Question", "name": "Les conditions environnementales jouent-elles un rôle ?", "position": 29, "acceptedAnswer": { "@type": "Answer", "text": "Oui, des conditions comme la chaleur ou l'humidité peuvent exacerber les effets des pyridiniums." } }, { "@type": "Question", "name": "Les interactions médicamenteuses sont-elles un facteur de risque ?", "position": 30, "acceptedAnswer": { "@type": "Answer", "text": "Oui, certaines interactions médicamenteuses peuvent augmenter la toxicité des pyridiniums." } } ] } ] }

Sources (2029 au total)

"Long-term follow-up of liver transplantation in incidental intrahepatic cholangiocarcinoma and mixed hepatocellular-cholangiocarcinoma".

The standard treatment for intrahepatic cholangiocarcinoma (iCCA) and mixed hepatocellular-cholangiocarcinoma (HCC-CC) is surgical resection, nevertheless, recent studies show adequate survival rates ... A retrospective cohort study was design including all patients undergoing LT at our center between January, 2006 and December, 2019 with incidentally diagnosed iCCA or HCC-CC after pathological examin... There were no iCCA or HCC-CC recurrences during the follow-up, and hence, there were no tumor related deaths. Global and disease-free survival were the same. The 1, 3 and 5-years patient survival were... These results suggest that LT could be an option in patients with chronic liver disease who develop an iCCA or HCC-CC, even in highly selected advanced tumors, but we must be cautious when analyzing t...

Hepatic artery resection in distal cholangiocarcinoma.

This study aimed to elucidate the safety and oncological outcomes of surgery with hepatic artery resection (HAR) for patients with distal cholangiocarcinoma.... The clinical data of patients with distal cholangiocarcinoma who underwent curative intent surgery at Hiroshima University between March 2009 and January 2021 were retrospectively analyzed. Eligible p... Among the 60 patients analyzed, eight patients had received HAR, and the remaining 52 patients had not. The rate of portal vein resection, T stage, and the number of metastasized lymph nodes in the HA... Patients with distal cholangiocarcinoma who underwent surgery with HAR tended to show early recurrences, although HAR could be performed safely....

Cholangiocarcinoma Attributed to Occupation: A Systematic Reviews.

The occurrence of a cluster of occupational cholangiocarcinoma(CCA) cases among Japanese workers at a small offset printing plant led to the hypotheses that occupational exposure was the root cause of... To conduct a systematic review on the cause of CCA in relation to occupation.... The systematic review included papers published between 1980 and 2020. Databases included PubMed, Science Direct, CINAHL, ProQuest Medical Library, Springer, Wiley online library, and the Cochrane lib... The review revealed that ten observational studies met the eligibility criteria. There was heterogeneity of occupational exposure assessment and the reported results. The possible carcinogens statisti... Despite the limited number of studies reviewed, the hypothesis of occupational risk for CCA was supported. Occupational health and safety measures may decrease exposure to these carcinogens, and surve...

Pathological survey of precursor lesions in cholangiocarcinoma.

To clarify the pathological significance of two precursors (high-grade biliary intraepithelial neoplasm [BilIN] and intraductal papillary neoplasm of bile duct [IPNB]) in cholangiocarcinomas (CCAs).... Ninety-one cases of CCA (47 distal CCAs [dCCAs], 31 perihilar CCAs [pCCAs] and 13 intrahepatic CCAs of large duct type [LD-iCCAs]) were examined for their association with precursors. Neoplastic intra... Fifty-four and 8 of 91 CCAs were associated with high-grade BilIN and IPNB, respectively, while these precursors were unidentifiable in the remaining CCAs. A majority of CCAs were of the gastrobiliary... CCAs were frequently associated with precursors; high-grade BilIN may be a major precursor and IPNB a minor one. CCAs with IPNB showed a favorable postoperative OS compared to CCAs with high-grade Bil...